A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations by Jonathan W. Riess, MD, MS, Matthew S. Lara, BS, Guillaume Luxardi, PhD, Miguel Lopez de Rodas, MD, Michiko Shimoda, PhD, Karen Kelly, MD, Primo N. Lara, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt A. Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD

Get full text